Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
April 27, 2009
- Majority of Major Drug Firms Increase Hiring of New Graduates in 2009
April 27, 2009
- Coefficients for Generics for DPC Hospitals May Be Introduced
April 27, 2009
- Yokohama Clinic Starts Cancer Therapy Using Dendritic Cells
April 27, 2009
- PMDA Creates New Office to Review Anticancer Drugs
April 27, 2009
- Asahi Kasei Licenses Flivas to Dong-A
April 27, 2009
- BUSINESS NEWS IN BRIEF
April 27, 2009
- Otsuka Aims at Further Growth Driven by Its Own Products in Oncology, CNS
April 27, 2009
- Drug Market in China to Reach US$50 Bil. in 2012
April 27, 2009
- Kowa, Apo Plus Station Creates "Career & Leaps" to Support Marketing of OTC Drugs
April 20, 2009
- Kissei's Urief Launched in the US
April 20, 2009
- Alpha MOS Sets Up Japanese Subsidiary
April 20, 2009
- Daiichi Sankyo, Eli Lilly Launch Prasugrel in UK
April 20, 2009
- Takara Bio Obtains License from Kyoto Univ.
April 20, 2009
- Eli Lilly Licenses Cialis to Nippon Shinyaku
April 20, 2009
- GE, Intel Ally in Home Health Technologies
April 20, 2009
- Otsuka, BMS Extend Agreement on Abilify, Embark on Global Oncology Collaboration
April 20, 2009
- Olympus Releases Biliary Stent Jointly with Medinol
April 20, 2009
- Pfizer Aims to Become Market Leader for Macrolides with Zithromac SR
April 20, 2009
- AMDD Inaugurated with Dr H. Wang as President
April 20, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…